Fosamax - drug for treatment of Paget disease, osteoporosis at women in a postmenopause, osteoporosis at men, a hypercalcemia at malignant tumors. Active alendronate ingredient - non-hormonal specific inhibitor of an osteoclastic bone resorption, suppresses osteoclasts. Taking of Fosamax stimulates bone formation, recovers positive balance between a resorption and recovery of a bone, progressively increases the mineral density of bones, promotes formation of a normal bone tissue with normal histologic structure.